The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
These holes would seem to have confirmed the folding hypothesis, but of most interest was the intersection in MAP-098 of a previously unknown, thick, high-grade structure (8.35m @ 14.27g/t Au, 49.92g/t Ag, 3.93%Zn), over 100m below any previous anomalous intersections, with an additional lower grade intersection over 100m further down again. The considerable distance from previous drilling is highly encouraging as it opens up large areas at depth as being potentially of interest, however, more drilling will now be required to confirm this.
Orosur CEO Brad George commented:
"Handing over operating control of Anzá was a complex and protracted process, slowing work and news flow. However, this effort was a necessary component of the evolution of the Project and is now reaping rewards as our major partners ramp up activities.
Covid-19 has now abated in the region to the extent that field activities can be undertaken more freely, and we look forward to major drill campaigns restarting on the exciting prospects that have been defined."
Dr Tim Mitchell, CEO of Sareum, commented:
"We continue to advance SDC-1801 towards its first clinical trial as a potential new treatment for autoimmune diseases including the acute respiratory symptoms of Covid-19. The preliminary findings from the safety and toxicology studies completed in late 2021 were highly encouraging and give us confidence in the promising safety profile of SDC-1801. We look forward to receiving the final report in the coming weeks, and to progressing our plan to begin the first clinical trial with SDC-1801 during H2 2022 - an important and exciting milestone for Sareum and supported by the substantial additional funding raised during 2021. These new funds will also enable us to accelerate the preclinical development of SDC-1802 through preclinical development.
"Furthermore, we are also very encouraged that Sierra Oncology is considering several clinical combination studies with SRA737 and that these may begin in the first half of 2022. We look forward to further updates on the clinical development of this candidate as the programme progresses."
Difficult to say, but there are many analysts saying even now that gold could hit £2500, or possibly 3000 this year. I doubt the later, but there are many indicators to suggest there will be a continued push upwards
Momentum building for sure. I'm also sure there are some serious gains to be made from here
We hit the 40's on less than we know now, many more positives, with Newmont & Agnico in the driving seat, and Gold on the rise again...Also we are lagging behind many Gold risers, think that's about to change
Some steller grades in these recent samples (which i am betting there will be) and licences in the bag and thing's will get very entertaining
I personally know a few HNWI, and they didn't get to where they are by behaving in a flippant way with there finances as you're describing. They did't become that wealthy from throwing large sums of money around on a "punt" and then just "forgetting about it". They are the most money conscious people out there, they don't want to lose what they have worked hard to accumulate, and rely on to keep up the expensive lifestyle
I did Bo77ock, well reasonably early, most in the 3's and 4's, up to the low 20's as well. Very happy with my average, but i have every confidence for those with high averages, with patience, to be well rewarded this year
Kat, you bring up good points regarding the slightly strange goings on with the big investors entry points, and lack of renewed buying at these prices? Hopefully a lot of positive progression going on in the background we just don't know about yet
Gunner, completely agree with that at this stage, at this price, the frustrating lack of updates, with little clarity on recent(ish) news, i think excepting a consolidation down at this level would be like shooting ourselves in the foot....with a sawn off shot gun
Exactly Sharetrader, that's what share trading in Low caps on platforms like AIM is all about for me, research the thing to death, if everything looks good, get in what your comfortable with before all the big announcements start rolling in, and the push upwards starts.
To me, everything has been, and still is, looking very good here. We shall see...
He said he thinks we are roughly two years behind GGP, and if memory serves, that was nearly a year ago. Speaks volumes, if we come anywhere that scenario in that time frame, we will all make a huge profits from here, or high priced purchases
This is what we are here in AIM for, not the ftse, the chance to make our small pot of money into a very much larger one, joining companies at the beginning of the journey. Agree completely with you WayneJ, add up all the info we have to date, and the 27m MCap looks ridiculously low IMO, the upside possibilities are huge, with very little negatives as far as I can see. I look forward to the next set of findings, and the granting of licenses to proceed to the much talked about NE & NW areas, then I believe the exciting times really will come. Hopefully not too far away